Physician profile
Darshankumar A Dave
NPI 1033155437
$2,513.82
in general payments reported to CMS, 2019-2025
13 companies · $370 in 2025
The $370 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $456 · 2021: $209 · 2022: $409 · 2023: $367 · 2024: $703 · 2025: $370.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,274 · Education: $167.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,273.84 |
| Education | $166.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,058.76 | 2021-2025 | Qulipta, Ubrelvy |
| Pfizer INC. | $313.44 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $235.56 | 2024-2025 | Breztri, Airsupra |
| Amgen INC. | $210.07 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $193.28 | 2019-2023 | Austedo Xr |
| Alexion Pharmaceuticals, INC. | $184.12 | 2022-2024 | Ultomiris |
| Lilly USA, LLC | $117.70 | 2024 | Jardiance |
| Argenx US, INC. | $107.37 | 2024-2025 | Vyvgart Hytrulo |
| Livanova USA, INC. | $27.60 | 2019 | |
| Boston Scientific Corporation | $18.40 | 2023 | Watchman Access System |
| Catalyst Pharmaceuticals, INC. | $16.72 | 2024 | |
| Neurocrine Biosciences, INC. | $15.42 | 2023 | Ingrezza |
| Biogen, INC. | $15.38 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Darshankumar Dave listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.